<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE collection SYSTEM "BioC.dtd">
<collection><source>PMC</source><date>20210104</date><key>pmc.key</key><document><id>6685706</id><infon key="license">author_manuscript</infon><passage><infon key="article-id_doi">10.1016/j.jid.2018.06.187</infon><infon key="article-id_manuscript">NIHMS1023170</infon><infon key="article-id_pmc">6685706</infon><infon key="article-id_pmid">30482597</infon><infon key="fpage">25</infon><infon key="issue">1</infon><infon key="license">
          This file is available for text mining. It may also be used consistent with the principles of fair use under the copyright law.
        </infon><infon key="lpage">30</infon><infon key="name_0">surname:Petrie;given-names:Tracy</infon><infon key="name_1">surname:Samatham;given-names:Ravikant</infon><infon key="name_2">surname:Witkowski;given-names:Alexander M.</infon><infon key="name_3">surname:Esteva;given-names:Andre</infon><infon key="name_4">surname:Leachman;given-names:Sancy A.</infon><infon key="section_type">TITLE</infon><infon key="type">front</infon><infon key="volume">139</infon><infon key="year">2020</infon><offset>0</offset><text>Melanoma Early Detection: Big Data, Bigger Picture</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>51</offset><text>Innovative technologies, including novel communication and imaging tools, are impacting dermatology in profound ways. A burning question for the field is whether we will retrospectively react to innovations or proactively leverage them to benefit precision medicine. Early detection of melanoma is a dermatologic area particularly poised to benefit from such innovation. This session of the Montagna Symposium on Biology of Skin focused on provocative, potentially disruptive advances, including: crowdsourcing of patient advocacy efforts, rigorous experimental design of public education campaigns, research with mobile phone applications, advanced skin imaging technologies, and the emergence of Artificial Intelligence (AI) as a diagnostic supplement.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>806</offset><text>INTRODUCTION</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>819</offset><text>The 2017 Montagna Symposium on the Biology of Skin - Precision Dermatology: Next Generation Prevention, Diagnosis, and Treatment - included a session focusing on Melanoma Early Detection: Big Data, Bigger Picture. In this session, technological advances in melanoma early detection were presented to illustrate how large electronic registries, imaging technologies, and artificial intelligence are beginning to be incorporated in science and medicine. Widespread use of internet communication tools, mobile devices, and social media is permitting crowdsourcing of potential study participants as well as initiation of nevus and melanoma image collection. These tools are also being used to feed larger, better data sets into ever-improving neural networks, empowering the development of artificial intelligence platforms. Most of these advances are in previously uncharted territory and will require that we begin to think in broader terms about their rigorous validation and subsequent application and integration into existing health and research systems that may be ill-prepared to transform as quickly as the technology.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>1944</offset><text>Early Detection of Melanoma</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1972</offset><text>Early detection has several advantages over treatment of late-stage cancer. Early detection reduces disfigurement by reducing the size and extent of surgical removal and reduces side effects that late-stage patients experience from systemic therapies. Early detection also prevents long-term side effects that may occur in individuals who would have had to use aggressive systemic therapies, and saves lives of individuals who would never have responded to these treatments. Finally, early detection is likely to reduce the overall care costs because early-stage treatments (eg. simple excision) are less expensive than those used in late-stage disease.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2626</offset><text>Of all cancers, melanoma is arguably one of the most straightforward to detect early because most melanomas present on visible areas of the skin and mucosa. This outward-facing property lends itself to a variety of screening opportunities, from whole-population screening programs to molecular and cellular modalities that take advantage of the accessibility of skin for imaging and sampling. Skin cancer screening of the general population with a total body skin examination may be safer, easier, and more cost effective than sophisticated screening methods, but this view has been controversial: the United States Preventive Services Task Force (USPSTF) has concluded that “a clear statement cannot be made about the benefit of skin cancer screening for melanoma mortality” due to insufficient evidence (Grade C,), and little data exists to prove the efficacy of this approach, though the USPSTF does recommend screening of higher risk populations.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>3581</offset><text>Results from a skin cancer screening program in Germany are mixed. In the non-randomized Schleswig-Holstein program, which included a public awareness campaign and an 8-hour primary care melanoma curriculum, more than 360,000 residents 21 years and older received total body skin examinations from dermatologists and trained primary care providers (PCP). A review of Cancer Registry data showed that incidence rates were greater and mortality rates dropped an estimated 45% for men and women in Schleswig-Holstein but not in nearby geographical areas during the 10-year study period. Although promising, when the Schleswig-Holstein program was extended nation-wide in Germany, analyses showed mixed results with respect to efficacy, raising significant questions about the validity of the results. Concerns were raised about data integrity, selection bias, and birth-cohort effects as possible causes for the inability to reproduce the results. There were also potentially important differences between the Schleswig-Holstein and German National programs that could account for the failure to replicate results, including a difference in the age of screening (21 and older versus 35 and older), a discontinuation of the public awareness campaign, and a difference in the referral requirements to dermatology.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>4890</offset><text>The War on Melanoma: Oregon’s Modifications on the German Experience</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>4961</offset><text>An evolving model for population-specific skin cancer screening, the War on Melanoma™ (WoM, https://www.ohsu.edu/xd/health/services/dermatology/war-on-melanoma/), is a comprehensive strategy for attacking melanoma in Oregon (and eventually beyond) and has attempted to resolve several of the criticisms of the Schleswig-Holstein-based German Program. For example, it has retained an education and public awareness campaign component, while also developing objective baseline metrics that will be followed longitudinally throughout the program (e.g., melanoma incidence and mortality, tumor depth, stage at diagnosis, obstacles to early detection that are experienced by melanoma patients, and cost of care). Given the rapid improvement in treatment of melanoma, it will be critical to determine if any reductions in mortality are due to the program or improved therapeutic outcome, so control states without access to the program will be used as comparators. In addition, the WoM is organized and stratified by population risk with the intent to apply different screening strategies to the different populations. It involves several population and participant groups and a variety of projects and is driven both by top-down and bottom-up efforts. Figure 1 shows the main ideas of different population types, different provider types, different screening and outreach methods by risk population, different empowerment methods by provider type, and the ideas that population classes are not uniformly sized nor are the lesions of risk classes seen with the same frequency by different provider types.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>6562</offset><text>Oregon, though seemingly an unlikely location to host a WoM, ranks sixth in overall incidence of melanoma in the nation according to the CDC, making it an ideal place to wage the war. In addition, Oregon has a population size and ethnic distribution similar in many ways to Schlesswig-Holstein and a state cancer registry. The Center for Health Systems Effectiveness at Oregon Health &amp; Science University will also facilitate baseline and follow-up measures of melanoma prognostic indicators and cost-effectiveness of melanoma screening. Together, these features make Oregon an excellent location for a pilot test of an early detection program.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>7207</offset><text>Grass-Roots Level Engagement of Melanoma Patients and Skin Care Service Professionals</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>7293</offset><text>One of the major “bottom-up” efforts has been the creation of a Melanoma Community Registry. The WoM began recruiting an “army” of Oregonians in June 2014, and this IRB-approved repository (the Melanoma Community Registry, IRB#10561) contains almost 8,000 research participants. These volunteers are committed to fighting melanoma through education, activism, and by participating in research surveys and other crowdsourced studies and trials. Importantly, part of the WoM program is a “teach the teachers” curriculum that includes lay-level material with accompanying competency-testing and pre-prepared, uniform teaching materials for those individuals who become WoM teachers. Formal validation of the curriculum began with focus sessions and testing at the 2018 WoM May Awareness Event in Portland, will continue throughout 2018, and has an official campaign planned to launch in May 2019. Similar tailored educational programs for skin-related service industries are in preparation for massage therapists, hairdressers, cosmetologists, body artists, midwives, etc. A formal partnership with the Oregon Health Authority has been developed that coordinates release of educational materials to all licensed groups. In this way the WoM has leveraged the interest of the community, provided standardized materials, and will expand the reach across the state substantially. Metrics such as the number of completed education modules, the number of training sessions that teachers perform and where they are held, and baseline knowledge level in a representative statewide population are expected to provide quantifiable data regarding uptake and effectiveness of the program.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>8979</offset><text>Top-Down Identification of Suspicious Lesions Statewide by Engagement of Medical Professionals</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>9074</offset><text>The WoM program for medical professionals builds upon the INFORMED curriculum (INternet curriculum FOR Melanoma Early Detection) that has demonstrated popularity and shown an increase in diagnostic skills in users but has not resulted in an increased rate of dermatology referrals or skin surgeries in Western Pennsylvania or the Veterans Affairs Palo Alto Health Care System. The WoM provider curriculum will be made available online, will be shared across the Oregon Health &amp; Science University’s (OHSU’s) PCP networks, and will be presented at OHSU-sponsored CME events. Metrics to evaluate uptake and efficacy will include the number of individuals who participated in CME courses, the location of their practices, the number of CME presentations made (and their location), and baseline knowledge testing on the diagnostic features of melanoma.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>9927</offset><text>Risk-Stratified, Population-Based Melanoma Screening Strategy</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>9989</offset><text>The risk of melanoma has been estimated in a variety of populations, including the general population, various phenotypic groups (e.g., individuals with lightly colored skin or hair, red hair, numerous freckles, numerous or atypical nevi, or who have had substantial ultraviolet radiation damage; see for review), and in individuals with a personal and/or family history of melanoma and those who carry a mutation in a melanoma predisposing gene. The WoM will target each population to enhance early detection using different methodology. In the general population, with risk estimates for melanoma incidence on the order of 1 in 100, the strategy will include a public awareness campaign, the use of social media, recommendations for tracking lesions with a free MoleMapper™ mobile phone app (see below), use of skin-related service professionals to help monitor clients’ skin, and recommendations to all health care providers to perform opportunistic screening when performing examination for other reasons. In populations at higher risk, a recommendation for a basic skin screening will be added, and in individuals identified with suspicious lesions and/or a personal or family history of melanoma, other strategies will be employed. These strategies range from routine total body skin examination in a specialty clinic setting to the use of advanced technologies, such as in vivo confocal reflectance microscopy, or genetic testing. By applying a tiered approach, using safe, inexpensive, and readily available technology for general populations and reserving more sophisticated, labor-intensive, and expensive strategies on the appropriate high-risk populations, it is hoped that the outcome can be improved.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>11708</offset><text>MoleMapper™: A Personal, Free, Quantitative Mole-Tracking Tool</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>11773</offset><text>MoleMapper™ is a free app that helps users to photographically track changes to skin lesions. Although MoleMapper™ does not triage participants or provide a diagnostic readout at this time, it does allow users to optionally consent to participate in a research project that makes image data available for data analysis challenges. It was first released in October 2015 as the Apple ResearchKit app focused on melanoma and has been continuously improved since then. The app has three primary goals: to provide a mole-tracking tool to individuals, to help facilitate health care visits, and to enable research. MoleMapper™ empowers the general population to effectively track changes in their moles, both visually and quantitatively. By including a reference coin of known size in photographs, the size of a lesion can be determined, and changes can be tracked over time. A downstream benefit of using MoleMapper™ is that having the images available at the time of a clinical visit can facilitate a more data-based assessment of a lesion’s risk of being a melanoma. A further source of information for providers is a visual history of the lesion. MoleMapper™ gives patients the ability to provide a monthly sequence of images so the provider can detect if and how it has changed over time.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>13073</offset><text>Finally, MoleMapper™ is a tool that is enabling crowd-sourced research. Since at least the early 1990s, the computer science community has been attempting to detect melanomas in images. Many premature claims were made during this time, usually by assessing performance on very small data sets. Recent progress has been encouraging because it uses Deep Learning algorithms that have been proven successful in other domains and because data set sizes are larger.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>13536</offset><text>Unfortunately, the largest data sets are still closed and research restricted to a small number of institutions. Additionally, work is still based on single images of a lesion and presumes high quality image inputs to systems, which may not always be true. It remains unclear whether images collected by a lay person on a mobile phone will be of sufficient quality to allow image diagnostics. The MoleMapper™ project aims to address both of these issues. By making a curated data set public, any qualified research group in projects related to lesion detection and classification can engage. The study will also provide a richer data set consisting of longitudinal images of lesions, peer lesions from the same participant, and images of non-lesional skin. We believe these three forms of context will enhance the ability to detect not whether a lesion has become melanoma, but whether it is likely to become melanoma.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>14457</offset><text>Non-Invasive Diagnostic Imaging Technologies to Improve Early Detection</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>14529</offset><text>Skin tumor diagnosis can be difficult due to the diverse clinical presentation of cutaneous lesions. In order to correctly identify an early melanoma, the use of dermoscopy, also known as dermatoscopy or epiluminescence microscopy, has been shown to significantly increase the sensitivity and specificity of diagnosis when compared with traditional naked-eye examination. Over the last decade, it has become a standard of initial screening in the United States. A dermatoscope uses a magnifier (typically x10 to x20) with both polarized and non-polarized light source that allows inspection of pigmented and non-pigmented skin structures without obstruction by skin surface reflection. In dermoscopically equivocal cases, lesions may be excised when further cytological information is required to rule out malignancy. The efficacy of benign tumor differentiation from melanoma can be measured by the number needed to excise ratio (NNE), for which dermoscopy ranges between 8.7 to 29.4, according to the level of expertise and clinical setting.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>15573</offset><text>For those patients who have been initially screened with handheld dermoscopy and identified as high-risk, digital dermoscopy may be of benefit to document their pigmented skin lesions. This technique originally was termed videodermoscopy and has of late been termed sequential digital dermoscopy. The digital dermoscopy images can be used for follow up, enabling an objective follow-up of skin lesions (moles) that may be of concern on initial presentation, allowing for identification of architectural changes in dermoscopy images over time, and precise triage of skin lesions for further biopsy, if needed.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>16182</offset><text>Reflectance confocal microscopy (RCM) is a novel technique enabling in vivo examination of the skin at cellular-level resolution with an excellent diagnostic accuracy. This procedure is painless, takes an average of 5 minutes, and offers an alternative to traditional skin biopsies. In the past decade RCM use in clinical practice has been shown to further improve early skin cancer diagnosis and help to significantly reduce the number of unnecessary excisions, with reduction of the NNE down to 6.25. The reflective confocal microscope works by highlighting a single point in the skin and allows frontal visualization (horizontal plane) of the skin with a resolution at the cellular level (0.5–1.0 μm in the transverse dimension and 4–5 μm in the axial dimension). The contrast in RCM images is based on the difference in the reflectance of the tissue depending on the chemical and molecular structures. The commercially used RCM Vivascope 1500 (Caliber Imaging and Diagnostics, Inc., Rochester, New York, USA) uses a laser diode with a near infrared wavelength of 830 nm, which permits the imaging depth to 300 μm, providing sufficient visual information to differentiate benign skin lesions from keratinocyte carcinoma and melanoma without damaging tissue. With the recent adoption of CPT codes for RCM in the United States, this technique shows a promising future and is gaining traction to help streamline precision screening of skin cancer in clinical settings.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>17658</offset><text>Using Deep Learning and Artificial Intelligence to Improve Melanoma Early Detection</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>17742</offset><text>In traditional computer programming, data inputs are processed by hand-crafted programs to generate outputs. Machine learning, in contrast, takes data inputs and outputs to train computer-generated programs. These computer-generated programs can then take new inputs and infer outputs. This approach makes predictive systems far more robust and generalizable than hand-crafted programs. Neural networks, a type of machine learning algorithm in which data is processed sequentially through a series of layers, have progressed significantly in recent years, achieving unprecedented milestones across a number of key artificial intelligence (AI) tasks ranging from computer vision tasks to natural language processing to game playing. These strides have been contingent on the aggregation of large-scale datasets with which to train these algorithms.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>18590</offset><text>Convolutional neural networks (CNNs), a type of neural network algorithm that has proven effective for tasks involving images, have achieved human-level accuracy at the task of object recognition. In this task, a computer must identify the class of an object displayed in an image. To do so, the network is typically first trained on a large corpus of images (input data) and object labels (outputs), containing around 1,000 object classes and over 1,000 different example images per class. This first step, called pre-training, embeds into the network many of the natural statistics of images: the presence of horizontal and vertical lines, naturally-occurring color schemes, etc. In the second step, called fine-tuning, this network is further trained on the final object classes of interest, typically with less data than during pre-training.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>19436</offset><text>CNNs, applied in dermatology, offer the unique opportunity to improve the diagnostic accuracy and early detection of malignancies. It has been shown that a CNN pre-trained on the ImageNet dataset, then further fine-tuned on ~130,000 images of various skin lesions, matched the performance of board-certified dermatologists at discerning benign from malignant neoplasms using photographic and dermoscopic images. In this study, ~24 dermatologists were tested for their ability to discriminate between benign and malignant pigmented lesions (melanomas, nevi), as well as benign and malignant epidermal lesions (basal and squamous cell carcinomas, seborrheic keratosis). In each case, the algorithm performed on par with all tested experts. Similar results were recently reported by.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>20217</offset><text>Such an algorithm, deployed on mobile devices, could assist a variety of healthcare practitioners at identifying malignancies early, when survival probability is significantly higher. The algorithm is similarly compatible with total body scanners and can be used to identify concerning lesions amongst a myriad of benign ones, potentially helping patients with basal cell nevus carcinoma syndrome or equivalently challenging cases.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>20649</offset><text>CONCLUSION</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>20660</offset><text>The early detection of melanoma is a laudable goal from the perspective of saving lives, reducing morbidity, and perhaps reducing health care costs. However, it is also a field that is ripe for the implementation of novel tools, applied in effective ways, if rigorous processes are put in place. The tools and processes that are evolving for the purpose of early detection of melanoma have the potential to guide similar development in other areas of medicine.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">footnote</infon><offset>21121</offset><text>CONFLICT OF INTEREST</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">footnote</infon><offset>21142</offset><text>The authors state no conflict of interest.</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">title</infon><offset>21185</offset><text>Abbreviations Used:</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>21205</offset><text>WoM</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>21209</offset><text>War on Melanoma</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>21225</offset><text>PCP</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>21229</offset><text>primary care provider</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>21251</offset><text>RCM</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>21255</offset><text>reflectance confocal microscopy</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>21287</offset><text>AI</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>21290</offset><text>artificial intelligence</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>21314</offset><text>CNN</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>21318</offset><text>Convolutional neural network</text></passage><passage><infon key="section_type">REF</infon><infon key="type">title</infon><offset>21347</offset><text>REFERENCES</text></passage><passage><infon key="fpage">14</infon><infon key="issue">1</infon><infon key="lpage">25</infon><infon key="name_0">surname:Alcon;given-names:JF</infon><infon key="name_1">surname:Ciuhu;given-names:C</infon><infon key="name_2">surname:Kate;given-names:W ten</infon><infon key="name_3">surname:Heinrich;given-names:A</infon><infon key="name_4">surname:Uzunbajakava;given-names:N</infon><infon key="name_5">surname:Krekels;given-names:G</infon><infon key="section_type">REF</infon><infon key="source">IEEE J. Sel. Top. Signal Process</infon><infon key="type">ref</infon><infon key="volume">3</infon><infon key="year">2009</infon><offset>21358</offset><text>Automatic Imaging System With Decision Support for Inspection of Pigmented Skin Lesions and Melanoma Diagnosis.</text></passage><passage><infon key="fpage">1046</infon><infon key="issue">10</infon><infon key="lpage">51</infon><infon key="name_0">surname:Anders;given-names:MP</infon><infon key="name_1">surname:Fengler;given-names:S</infon><infon key="name_2">surname:Volkmer;given-names:B</infon><infon key="name_3">surname:Greinert;given-names:R</infon><infon key="name_4">surname:Breitbart;given-names:EW</infon><infon key="pub-id_pmid">28832980</infon><infon key="section_type">REF</infon><infon key="source">Int. J. Dermatol</infon><infon key="type">ref</infon><infon key="volume">56</infon><infon key="year">2017</infon><offset>21470</offset><text>Nationwide skin cancer screening in Germany: Evaluation of the training program.</text></passage><passage><infon key="comment">e1</infon><infon key="fpage">54</infon><infon key="issue">1</infon><infon key="lpage">59</infon><infon key="name_0">surname:Argenziano;given-names:G</infon><infon key="name_1">surname:Cerroni;given-names:L</infon><infon key="name_2">surname:Zalaudek;given-names:I</infon><infon key="name_3">surname:Staibano;given-names:S</infon><infon key="name_4">surname:Hofmann-Wellenhof;given-names:R</infon><infon key="name_5">surname:Arpaia;given-names:N</infon><infon key="pub-id_pmid">21982636</infon><infon key="section_type">REF</infon><infon key="source">J. Am. Acad. Dermatol</infon><infon key="type">ref</infon><infon key="volume">67</infon><infon key="year">2012</infon><offset>21551</offset><text>Accuracy in melanoma detection: A 10-year multicenter survey.</text></passage><passage><infon key="fpage">161</infon><infon key="issue">2</infon><infon key="lpage">7</infon><infon key="name_0">surname:Argenziano;given-names:G</infon><infon key="name_1">surname:Moscarella;given-names:E</infon><infon key="name_2">surname:Annetta;given-names:A</infon><infon key="name_3">surname:Battarra;given-names:VC</infon><infon key="name_4">surname:Brunetti;given-names:B</infon><infon key="name_5">surname:Buligan;given-names:C</infon><infon key="pub-id_pmid">24819635</infon><infon key="section_type">REF</infon><infon key="source">G. Ital. Dermatol. Venereol</infon><infon key="type">ref</infon><infon key="volume">149</infon><infon key="year">2014</infon><offset>21613</offset><text>Melanoma detection in Italian pigmented lesion clinics.</text></passage><passage><infon key="fpage">1029</infon><infon key="issue">5</infon><infon key="lpage">38</infon><infon key="name_0">surname:Blum;given-names:A</infon><infon key="name_1">surname:Luedtke;given-names:H</infon><infon key="name_2">surname:Ellwanger;given-names:U</infon><infon key="name_3">surname:Schwabe;given-names:R</infon><infon key="name_4">surname:Rassner;given-names:G</infon><infon key="name_5">surname:Garbe;given-names:C</infon><infon key="pub-id_pmid">15541081</infon><infon key="section_type">REF</infon><infon key="source">Br. J. Dermatol</infon><infon key="type">ref</infon><infon key="volume">151</infon><infon key="year">2004</infon><offset>21669</offset><text>Digital image analysis for diagnosis of cutaneous melanoma. Development of a highly effective computer algorithm based on analysis of 837 melanocytic lesions.</text></passage><passage><infon key="fpage">163</infon><infon key="issue">3</infon><infon key="lpage">70</infon><infon key="name_0">surname:Cascinelli;given-names:N</infon><infon key="name_1">surname:Ferrario;given-names:M</infon><infon key="name_2">surname:Bufalino;given-names:R</infon><infon key="name_3">surname:Zurrida;given-names:S</infon><infon key="name_4">surname:Galimberti;given-names:V</infon><infon key="name_5">surname:Mascheroni;given-names:L</infon><infon key="pub-id_pmid">1450670</infon><infon key="section_type">REF</infon><infon key="source">Melanoma Res</infon><infon key="type">ref</infon><infon key="volume">2</infon><infon key="year">1992</infon><offset>21828</offset><text>Results obtained by using a computerized image analysis system designed as an aid to diagnosis of cutaneous melanoma.</text></passage><passage><infon key="comment">Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/jdv.14791</infon><infon key="fpage">1284</infon><infon key="lpage">1291</infon><infon key="name_0">surname:Cinotti;given-names:E</infon><infon key="name_1">surname:Labeille;given-names:B</infon><infon key="name_2">surname:Debarbieux;given-names:S</infon><infon key="name_3">surname:Carrera;given-names:C</infon><infon key="name_4">surname:Lacarrubba;given-names:F</infon><infon key="name_5">surname:Witkowski;given-names:AM</infon><infon key="pub-id_pmid">29341263</infon><infon key="section_type">REF</infon><infon key="source">J. Eur. Acad. Dermatol. Venereol</infon><infon key="type">ref</infon><infon key="volume">32</infon><infon key="year">2018</infon><offset>21946</offset><text>Dermoscopy vs. reflectance confocal microscopy for the diagnosis of lentigo maligna.</text></passage><passage><infon key="fpage">5:1</infon><infon key="issue">4</infon><infon key="lpage">5:15</infon><infon key="name_0">surname:Codella;given-names:NCF</infon><infon key="name_1">surname:Nguyen;given-names:QB</infon><infon key="name_2">surname:Pankanti;given-names:S</infon><infon key="name_3">surname:Gutman;given-names:DA</infon><infon key="name_4">surname:Helba;given-names:B</infon><infon key="name_5">surname:Halpern;given-names:AC</infon><infon key="section_type">REF</infon><infon key="source">IBM J. Res. Dev</infon><infon key="type">ref</infon><infon key="volume">61</infon><infon key="year">2017</infon><offset>22031</offset><text>Deep learning ensembles for melanoma recognition in dermoscopy images.</text></passage><passage><infon key="fpage">648</infon><infon key="issue">6</infon><infon key="lpage">57</infon><infon key="name_0">surname:Eide;given-names:MJ</infon><infon key="name_1">surname:Asgari;given-names:MM</infon><infon key="name_2">surname:Fletcher;given-names:SW</infon><infon key="name_3">surname:Geller;given-names:AC</infon><infon key="name_4">surname:Halpern;given-names:AC</infon><infon key="name_5">surname:Shaikh;given-names:WR</infon><infon key="pub-id_pmid">24204061</infon><infon key="section_type">REF</infon><infon key="source">J. Am. Board Fam. Med</infon><infon key="type">ref</infon><infon key="volume">26</infon><infon key="year">2013</infon><offset>22102</offset><text>Effects on Skills and Practice from a Web-Based Skin Cancer Course for Primary Care Providers.</text></passage><passage><infon key="fpage">43</infon><infon key="issue">1</infon><infon key="lpage">50</infon><infon key="name_0">surname:Eisemann;given-names:N</infon><infon key="name_1">surname:Waldmann;given-names:A</infon><infon key="name_2">surname:Geller;given-names:AC</infon><infon key="name_3">surname:Weinstock;given-names:MA</infon><infon key="name_4">surname:Volkmer;given-names:B</infon><infon key="name_5">surname:Greinert;given-names:R</infon><infon key="pub-id_pmid">23877569</infon><infon key="section_type">REF</infon><infon key="source">J. Invest. Dermatol</infon><infon key="type">ref</infon><infon key="volume">134</infon><infon key="year">2014</infon><offset>22197</offset><text>Non-Melanoma Skin Cancer Incidence and Impact of Skin Cancer Screening on Incidence.</text></passage><passage><infon key="fpage">115</infon><infon key="issue">7639</infon><infon key="lpage">8</infon><infon key="name_0">surname:Esteva;given-names:A</infon><infon key="name_1">surname:Kuprel;given-names:B</infon><infon key="name_2">surname:Novoa;given-names:RA</infon><infon key="name_3">surname:Ko;given-names:J</infon><infon key="name_4">surname:Swetter;given-names:SM</infon><infon key="name_5">surname:Blau;given-names:HM</infon><infon key="pub-id_pmid">28117445</infon><infon key="section_type">REF</infon><infon key="source">Nature</infon><infon key="type">ref</infon><infon key="volume">542</infon><infon key="year">2017</infon><offset>22282</offset><text>Dermatologist-level classification of skin cancer with deep neural networks.</text></passage><passage><infon key="fpage">742</infon><infon key="issue">9</infon><infon key="lpage">55</infon><infon key="name_0">surname:Gola Isasi;given-names:A</infon><infon key="name_1">surname:García Zapirain;given-names:B</infon><infon key="name_2">surname:Méndez Zorrilla;given-names:A</infon><infon key="pub-id_pmid">21767831</infon><infon key="section_type">REF</infon><infon key="source">Comput. Biol. Med</infon><infon key="type">ref</infon><infon key="volume">41</infon><infon key="year">2011</infon><offset>22359</offset><text>Melanomas non-invasive diagnosis application based on the ABCD rule and pattern recognition image processing algorithms.</text></passage><passage><infon key="name_0">surname:Goodfellow;given-names:I</infon><infon key="name_1">surname:Bengio;given-names:Y</infon><infon key="name_2">surname:Courville;given-names:A</infon><infon key="section_type">REF</infon><infon key="source">Deep Learning</infon><infon key="type">ref</infon><infon key="year">2016</infon><offset>22480</offset></passage><passage><infon key="fpage">231</infon><infon key="issue">4</infon><infon key="lpage">6</infon><infon key="name_0">surname:Green;given-names:A</infon><infon key="name_1">surname:Martin;given-names:N</infon><infon key="name_2">surname:McKenzie;given-names:G</infon><infon key="name_3">surname:Pfitzner;given-names:J</infon><infon key="name_4">surname:Quintarelli;given-names:F</infon><infon key="name_5">surname:Thomas;given-names:BW</infon><infon key="pub-id_pmid">1823631</infon><infon key="section_type">REF</infon><infon key="source">Melanoma Res</infon><infon key="type">ref</infon><infon key="volume">1</infon><infon key="year">1991</infon><offset>22481</offset><text>Computer image analysis of pigmented skin lesions.</text></passage><passage><infon key="fpage">2386</infon><infon key="issue">10</infon><infon key="lpage">94</infon><infon key="name_0">surname:Guitera;given-names:P</infon><infon key="name_1">surname:Menzies;given-names:SW</infon><infon key="name_2">surname:Longo;given-names:C</infon><infon key="name_3">surname:Cesinaro;given-names:AM</infon><infon key="name_4">surname:Scolyer;given-names:RA</infon><infon key="name_5">surname:Pellacani;given-names:G</infon><infon key="pub-id_pmid">22718115</infon><infon key="section_type">REF</infon><infon key="source">J. Invest. Dermatol</infon><infon key="type">ref</infon><infon key="volume">132</infon><infon key="year">2012</infon><offset>22532</offset><text>In Vivo Confocal Microscopy for Diagnosis of Melanoma and Basal Cell Carcinoma Using a Two-Step Method: Analysis of 710 Consecutive Clinically Equivocal Cases.</text></passage><passage><infon key="fpage">2080</infon><infon key="issue">8</infon><infon key="lpage">91</infon><infon key="name_0">surname:Guitera;given-names:P</infon><infon key="name_1">surname:Pellacani;given-names:G</infon><infon key="name_2">surname:Crotty;given-names:KA</infon><infon key="name_3">surname:Scolyer;given-names:RA</infon><infon key="name_4">surname:Li;given-names:L-XL</infon><infon key="name_5">surname:Bassoli;given-names:S</infon><infon key="pub-id_pmid">20393481</infon><infon key="section_type">REF</infon><infon key="source">J. Invest. Dermatol</infon><infon key="type">ref</infon><infon key="volume">130</infon><infon key="year">2010</infon><offset>22692</offset><text>The Impact of In Vivo Reflectance Confocal Microscopy on the Diagnostic Accuracy of Lentigo Maligna and Equivocal Pigmented and Nonpigmented Macules of the Face.</text></passage><passage><infon key="fpage">131</infon><infon key="issue">1</infon><infon key="lpage">8</infon><infon key="name_0">surname:Guitera;given-names:P</infon><infon key="name_1">surname:Pellacani;given-names:G</infon><infon key="name_2">surname:Longo;given-names:C</infon><infon key="name_3">surname:Seidenari;given-names:S</infon><infon key="name_4">surname:Avramidis;given-names:M</infon><infon key="name_5">surname:Menzies;given-names:SW</infon><infon key="pub-id_pmid">18633444</infon><infon key="section_type">REF</infon><infon key="source">J. Invest. Dermatol</infon><infon key="type">ref</infon><infon key="volume">129</infon><infon key="year">2009</infon><offset>22854</offset><text>In Vivo Reflectance Confocal Microscopy Enhances Secondary Evaluation of Melanocytic Lesions.</text></passage><passage><infon key="comment">Available from: https://academic.oup.com/annonc/advance-article/doi/10.1093/annonc/mdy166/5004443</infon><infon key="name_0">surname:Haenssle;given-names:HA</infon><infon key="name_1">surname:Fink;given-names:C</infon><infon key="name_2">surname:Schneiderbauer;given-names:R</infon><infon key="name_3">surname:Toberer;given-names:F</infon><infon key="name_4">surname:Buhl;given-names:T</infon><infon key="name_5">surname:Blum;given-names:A</infon><infon key="section_type">REF</infon><infon key="source">Ann. Oncol</infon><infon key="type">ref</infon><offset>22948</offset><text>Man against machine: diagnostic performance of a deep learning convolutional neural network for dermoscopic melanoma recognition in comparison to 58 dermatologists.</text></passage><passage><infon key="comment">[cited 2018 Apr 23]. Available from: https://link.springer.com/chapter/10.1007/978-3-642-60771-4_121</infon><infon key="fpage">1052</infon><infon key="lpage">63</infon><infon key="name_0">surname:Husemann;given-names:R</infon><infon key="name_1">surname:Tölg;given-names:S</infon><infon key="name_2">surname:Seelen;given-names:WV</infon><infon key="name_3">surname:Altmeyer;given-names:P</infon><infon key="name_4">surname:Frosch;given-names:PJ</infon><infon key="name_5">surname:Stücker;given-names:M</infon><infon key="section_type">REF</infon><infon key="source">Skin Cancer UV Radiat</infon><infon key="type">ref</infon><infon key="year">1997</infon><offset>23113</offset></passage><passage><infon key="fpage">272</infon><infon key="issue">2</infon><infon key="lpage">9</infon><infon key="name_0">surname:Jiang;given-names:AJ</infon><infon key="name_1">surname:Eide;given-names:MJ</infon><infon key="name_2">surname:Alexander;given-names:GL</infon><infon key="name_3">surname:Altschuler;given-names:A</infon><infon key="name_4">surname:Asgari;given-names:MM</infon><infon key="name_5">surname:Geller;given-names:AC</infon><infon key="pub-id_pmid">26391994</infon><infon key="section_type">REF</infon><infon key="source">J. Cancer Educ</infon><infon key="type">ref</infon><infon key="volume">32</infon><infon key="year">2017</infon><offset>23114</offset><text>Providers’ Experiences with a Melanoma Web-Based Course: a Discussion on Barriers and Intentions.</text></passage><passage><infon key="fpage">13</infon><infon key="issue">1</infon><infon key="lpage">37</infon><infon key="name_0">surname:Johnson;given-names:MM</infon><infon key="name_1">surname:Leachman;given-names:SA</infon><infon key="name_2">surname:Aspinwall;given-names:LG</infon><infon key="name_3">surname:Cranmer;given-names:LD</infon><infon key="name_4">surname:Curiel-Lewandrowski;given-names:C</infon><infon key="name_5">surname:Sondak;given-names:VK</infon><infon key="pub-id_pmid">28758010</infon><infon key="section_type">REF</infon><infon key="source">Melanoma Manag</infon><infon key="type">ref</infon><infon key="volume">4</infon><infon key="year">2017</infon><offset>23214</offset><text>Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy.</text></passage><passage><infon key="fpage">355</infon><infon key="issue">3</infon><infon key="lpage">67</infon><infon key="name_0">surname:Kaiser;given-names:M</infon><infon key="name_1">surname:Schiller;given-names:J</infon><infon key="name_2">surname:Schreckenberger;given-names:C</infon><infon key="pub-id_pmid">28353004</infon><infon key="section_type">REF</infon><infon key="source">Eur. J. Health Econ</infon><infon key="type">ref</infon><infon key="volume">19</infon><infon key="year">2018</infon><offset>23357</offset><text>The effectiveness of a population-based skin cancer screening program: evidence from Germany.</text></passage><passage><infon key="fpage">5395</infon><infon key="issue">21</infon><infon key="lpage">402</infon><infon key="name_0">surname:Katalinic;given-names:A</infon><infon key="name_1">surname:Waldmann;given-names:A</infon><infon key="name_2">surname:Weinstock;given-names:MA</infon><infon key="name_3">surname:Geller;given-names:AC</infon><infon key="name_4">surname:Eisemann;given-names:N</infon><infon key="name_5">surname:Greinert;given-names:R</infon><infon key="pub-id_pmid">22517033</infon><infon key="section_type">REF</infon><infon key="source">Cancer</infon><infon key="type">ref</infon><infon key="volume">118</infon><infon key="year">2012</infon><offset>23451</offset><text>Does skin cancer screening save lives?</text></passage><passage><infon key="fpage">159</infon><infon key="issue">3</infon><infon key="lpage">65</infon><infon key="name_0">surname:Kittler;given-names:H</infon><infon key="name_1">surname:Pehamberger;given-names:H</infon><infon key="name_2">surname:Wolff;given-names:K</infon><infon key="name_3">surname:Binder;given-names:M</infon><infon key="pub-id_pmid">11902502</infon><infon key="section_type">REF</infon><infon key="source">Lancet Oncol</infon><infon key="type">ref</infon><infon key="volume">3</infon><infon key="year">2002</infon><offset>23490</offset><text>Diagnostic accuracy of dermoscopy.</text></passage><passage><infon key="fpage">289</infon><infon key="issue">4</infon><infon key="lpage">93</infon><infon key="name_0">surname:Kornek;given-names:T</infon><infon key="name_1">surname:Schäfer;given-names:I</infon><infon key="name_2">surname:Reusch;given-names:M</infon><infon key="name_3">surname:Blome;given-names:C</infon><infon key="name_4">surname:Herberger;given-names:K</infon><infon key="name_5">surname:Beikert;given-names:FC</infon><infon key="pub-id_pmid">23295723</infon><infon key="section_type">REF</infon><infon key="source">Dermatology</infon><infon key="type">ref</infon><infon key="volume">225</infon><infon key="year">2012</infon><offset>23525</offset><text>Routine Skin Cancer Screening in Germany: Four Years of Experience from the Dermatologists’ Perspective.</text></passage><passage><infon key="fpage">84</infon><infon key="issue">6</infon><infon key="lpage">90</infon><infon key="name_0">surname:Krizhevsky;given-names:A</infon><infon key="name_1">surname:Sutskever;given-names:I</infon><infon key="name_2">surname:Hinton;given-names:GE</infon><infon key="section_type">REF</infon><infon key="source">Commun ACM</infon><infon key="type">ref</infon><infon key="volume">60</infon><infon key="year">2017</infon><offset>23632</offset><text>ImageNet Classification with Deep Convolutional Neural Networks.</text></passage><passage><infon key="comment">cited 2018 Apr 23 Available from: https://link.springer.com/chapter/10.1007/978-3-319-22539-5_3</infon><infon key="fpage">51</infon><infon key="lpage">105</infon><infon key="name_0">surname:Leachman;given-names:SA</infon><infon key="name_1">surname:Cassidy;given-names:PB</infon><infon key="name_2">surname:Chen;given-names:SC</infon><infon key="name_3">surname:Curiel;given-names:C</infon><infon key="name_4">surname:Geller;given-names:A</infon><infon key="name_5">surname:Gareau;given-names:D</infon><infon key="section_type">REF</infon><infon key="source">Melanoma</infon><infon key="type">ref</infon><infon key="year">2016</infon><offset>23697</offset></passage><passage><infon key="fpage">e0162495</infon><infon key="issue">9</infon><infon key="name_0">surname:Łudzik;given-names:J</infon><infon key="name_1">surname:Witkowski;given-names:AM</infon><infon key="name_2">surname:Roterman-Konieczna;given-names:I</infon><infon key="name_3">surname:Bassoli;given-names:S</infon><infon key="name_4">surname:Farnetani;given-names:F</infon><infon key="name_5">surname:Pellacani;given-names:G</infon><infon key="pub-id_pmid">27606812</infon><infon key="section_type">REF</infon><infon key="source">PLOS ONE</infon><infon key="type">ref</infon><infon key="volume">11</infon><infon key="year">2016</infon><offset>23698</offset><text>Improving Diagnostic Accuracy of Dermoscopically Equivocal Pink Cutaneous Lesions with Reflectance Confocal Microscopy in Telemedicine Settings: Double Reader Concordance Evaluation of 316 Cases.</text></passage><passage><infon key="fpage">653</infon><infon key="issue">6</infon><infon key="lpage">64</infon><infon key="name_0">surname:Oh;given-names:A</infon><infon key="name_1">surname:Tran;given-names:DM</infon><infon key="name_2">surname:McDowell;given-names:LC</infon><infon key="name_3">surname:Keyvani;given-names:D</infon><infon key="name_4">surname:Barcelon;given-names:JA</infon><infon key="name_5">surname:Merino;given-names:O</infon><infon key="pub-id_pmid">28530525</infon><infon key="section_type">REF</infon><infon key="source">J. Manag. Care Spec. Pharm</infon><infon key="type">ref</infon><infon key="volume">23</infon><infon key="year">2017</infon><offset>23894</offset><text>Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States.</text></passage><passage><infon key="fpage">413</infon><infon key="issue">3</infon><infon key="lpage">9</infon><infon key="name_0">surname:Pellacani;given-names:G</infon><infon key="name_1">surname:Witkowski;given-names:A</infon><infon key="name_2">surname:Cesinaro;given-names:AM</infon><infon key="name_3">surname:Losi;given-names:A</infon><infon key="name_4">surname:Colombo;given-names:GL</infon><infon key="name_5">surname:Campagna;given-names:A</infon><infon key="pub-id_pmid">26446299</infon><infon key="section_type">REF</infon><infon key="source">J. Eur. Acad. Dermatol. Venereol</infon><infon key="type">ref</infon><infon key="volume">30</infon><infon key="year">2016</infon><offset>24053</offset><text>Cost–benefit of reflectance confocal microscopy in the diagnostic performance of melanoma.</text></passage><passage><infon key="fpage">936</infon><infon key="name_0">surname:Schoffer;given-names:O</infon><infon key="name_1">surname:Schülein;given-names:S</infon><infon key="name_2">surname:Arand;given-names:G</infon><infon key="name_3">surname:Arnholdt;given-names:H</infon><infon key="name_4">surname:Baaske;given-names:D</infon><infon key="name_5">surname:Bargou;given-names:RC</infon><infon key="pub-id_pmid">27919243</infon><infon key="section_type">REF</infon><infon key="source">BMC Cancer</infon><infon key="type">ref</infon><infon key="volume">16</infon><infon key="year">2016</infon><offset>24146</offset><text>Tumour stage distribution and survival of malignant melanoma in Germany 2002–2011.</text></passage><passage><infon key="fpage">85</infon><infon key="issue">2</infon><infon key="lpage">96</infon><infon key="name_0">surname:Shao;given-names:S</infon><infon key="name_1">surname:Grams;given-names:RR</infon><infon key="pub-id_pmid">7964215</infon><infon key="section_type">REF</infon><infon key="source">J. Med. Syst</infon><infon key="type">ref</infon><infon key="volume">18</infon><infon key="year">1994</infon><offset>24231</offset><text>A proposed computer diagnostic system for malignant melanoma (CDSMM).</text></passage><passage><infon key="fpage">1285</infon><infon key="issue">5</infon><infon key="lpage">98</infon><infon key="name_0">surname:Shin;given-names:HC</infon><infon key="name_1">surname:Roth;given-names:HR</infon><infon key="name_2">surname:Gao;given-names:M</infon><infon key="name_3">surname:Lu;given-names:L</infon><infon key="name_4">surname:Xu;given-names:Z</infon><infon key="name_5">surname:Nogues;given-names:I</infon><infon key="pub-id_pmid">26886976</infon><infon key="section_type">REF</infon><infon key="source">IEEE Trans. Med. Imaging</infon><infon key="type">ref</infon><infon key="volume">35</infon><infon key="year">2016</infon><offset>24301</offset><text>Deep Convolutional Neural Networks for Computer-Aided Detection: CNN Architectures, Dataset Characteristics and Transfer Learning.</text></passage><passage><infon key="fpage">83</infon><infon key="lpage">8</infon><infon key="name_0">surname:Stang;given-names:A</infon><infon key="name_1">surname:Garbe;given-names:C</infon><infon key="name_2">surname:Autier;given-names:P</infon><infon key="name_3">surname:Jöckel;given-names:K-H</infon><infon key="pub-id_pmid">27371911</infon><infon key="section_type">REF</infon><infon key="source">Eur. J. Cancer</infon><infon key="type">ref</infon><infon key="volume">64</infon><infon key="year">2016</infon><offset>24432</offset><text>The many unanswered questions related to the German skin cancer screening programme.</text></passage><passage><infon key="fpage">432</infon><infon key="issue">3</infon><infon key="lpage">7</infon><infon key="name_0">surname:Stang;given-names:A</infon><infon key="name_1">surname:Jöckel;given-names:K-H</infon><infon key="pub-id_pmid">26480048</infon><infon key="section_type">REF</infon><infon key="source">Cancer</infon><infon key="type">ref</infon><infon key="volume">122</infon><infon key="year">2016</infon><offset>24517</offset><text>Does skin cancer screening save lives? A detailed analysis of mortality time trends in Schleswig-Holstein and Germany.</text></passage><passage><infon key="fpage">303</infon><infon key="issue">3</infon><infon key="lpage">12</infon><infon key="name_0">surname:Stang;given-names:A</infon><infon key="name_1">surname:Jöckel;given-names:K-H</infon><infon key="name_2">surname:Heidinger;given-names:O</infon><infon key="pub-id_pmid">29294207</infon><infon key="section_type">REF</infon><infon key="source">Eur. J. Epidemiol</infon><infon key="type">ref</infon><infon key="volume">33</infon><infon key="year">2018</infon><offset>24636</offset><text>Skin cancer rates in North Rhine-Westphalia, Germany before and after the introduction of the nationwide skin cancer screening program (2000–2015).</text></passage><passage><infon key="fpage">365</infon><infon key="issue">2</infon><infon key="lpage">71</infon><infon key="name_0">surname:Stanganelli;given-names:I</infon><infon key="name_1">surname:Longo;given-names:C</infon><infon key="name_2">surname:Mazzoni;given-names:L</infon><infon key="name_3">surname:Magi;given-names:S</infon><infon key="name_4">surname:Medri;given-names:M</infon><infon key="name_5">surname:Lanzanova;given-names:G</infon><infon key="pub-id_pmid">25154446</infon><infon key="section_type">REF</infon><infon key="source">Br. J. Dermatol</infon><infon key="type">ref</infon><infon key="volume">172</infon><infon key="year">2015</infon><offset>24786</offset><text>Integration of reflectance confocal microscopy in sequential dermoscopy follow-up improves melanoma detection accuracy.</text></passage><passage><infon key="fpage">797</infon><infon key="issue">8</infon><infon key="lpage">801</infon><infon key="name_0">surname:Swetter;given-names:SM</infon><infon key="name_1">surname:Chang;given-names:J</infon><infon key="name_2">surname:Shaub;given-names:AR</infon><infon key="name_3">surname:Weinstock;given-names:MA</infon><infon key="name_4">surname:Lewis;given-names:ET</infon><infon key="name_5">surname:Asch;given-names:SM</infon><infon key="pub-id_pmid">28593242</infon><infon key="section_type">REF</infon><infon key="source">JAMA Dermatol</infon><infon key="type">ref</infon><infon key="volume">153</infon><infon key="year">2017</infon><offset>24906</offset><text>Primary Care–Based Skin Cancer Screening in a Veterans Affairs Health Care System.</text></passage><passage><infon key="fpage">669</infon><infon key="issue">3</infon><infon key="lpage">76</infon><infon key="name_0">surname:Vestergaard;given-names:ME</infon><infon key="name_1">surname:Macaskill;given-names:P</infon><infon key="name_2">surname:Holt;given-names:PE</infon><infon key="name_3">surname:Menzies;given-names:SW</infon><infon key="pub-id_pmid">18616769</infon><infon key="section_type">REF</infon><infon key="source">Br. J. Dermatol</infon><infon key="type">ref</infon><infon key="volume">159</infon><infon key="year">2008</infon><offset>24991</offset><text>Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta-analysis of studies performed in a clinical setting.</text></passage><passage><infon key="fpage">970</infon><infon key="issue">5</infon><infon key="lpage">4</infon><infon key="name_0">surname:Waldmann;given-names:A</infon><infon key="name_1">surname:Nolte;given-names:S</infon><infon key="name_2">surname:Weinstock;given-names:MA</infon><infon key="name_3">surname:Breitbart;given-names:EW</infon><infon key="name_4">surname:Eisemann;given-names:N</infon><infon key="name_5">surname:Geller;given-names:AC</infon><infon key="pub-id_pmid">22294187</infon><infon key="section_type">REF</infon><infon key="source">Br. J. Cancer</infon><infon key="type">ref</infon><infon key="volume">106</infon><infon key="year">2012</infon><offset>25137</offset><text>Skin cancer screening participation and impact on melanoma incidence in Germany – an observational study on incidence trends in regions with and without population-based screening.</text></passage><passage><infon key="fpage">3152</infon><infon key="issue">20</infon><infon key="lpage">6</infon><infon key="name_0">surname:Weinstock;given-names:MA</infon><infon key="name_1">surname:Ferris;given-names:LK</infon><infon key="name_2">surname:Saul;given-names:MI</infon><infon key="name_3">surname:Geller;given-names:AC</infon><infon key="name_4">surname:Risica;given-names:PM</infon><infon key="name_5">surname:Siegel;given-names:JA</infon><infon key="pub-id_pmid">27391802</infon><infon key="section_type">REF</infon><infon key="source">Cancer</infon><infon key="type">ref</infon><infon key="volume">122</infon><infon key="year">2016</infon><offset>25320</offset><text>Downstream consequences of melanoma screening in a community practice setting: First results.</text></passage><passage><infon key="comment">[cited 2018 Apr 23]. Available from: https://www.uspreventiveservicestaskforce.org/Page/Document/draft-evidence-review159/skin-cancer-screening2</infon><infon key="name_0">surname:Wernli;given-names:KJ</infon><infon key="name_1">surname:Henrikson;given-names:NB</infon><infon key="name_2">surname:Morrison;given-names:CC</infon><infon key="name_3">surname:Nguyen;given-names:M</infon><infon key="name_4">surname:Pocobelli;given-names:G</infon><infon key="name_5">surname:Whitlock;given-names:EP</infon><infon key="section_type">REF</infon><infon key="source">Draft Evidence Review: Skin Cancer: Screening - US Preventive Services Task Force [Internet]</infon><infon key="type">ref</infon><infon key="year">2015</infon><offset>25414</offset></passage><passage><infon key="fpage">e0187748</infon><infon key="issue">11</infon><infon key="name_0">surname:Witkowski;given-names:AM</infon><infon key="name_1">surname:Łudzik;given-names:J</infon><infon key="name_2">surname:Arginelli;given-names:F</infon><infon key="name_3">surname:Bassoli;given-names:S</infon><infon key="name_4">surname:Benati;given-names:E</infon><infon key="name_5">surname:Casari;given-names:A</infon><infon key="pub-id_pmid">29121636</infon><infon key="section_type">REF</infon><infon key="source">PLOS ONE</infon><infon key="type">ref</infon><infon key="volume">12</infon><infon key="year">2017</infon><offset>25415</offset><text>Improving diagnostic sensitivity of combined dermoscopy and reflectance confocal microscopy imaging through double reader concordance evaluation in telemedicine settings: A retrospective study of 1000 equivocal cases.</text></passage><passage><infon key="comment">https://link.springer.com/protocol/10.1007/978-1-4939-2172-0_30</infon><infon key="fpage">459</infon><infon key="lpage">96</infon><infon key="name_0">surname:Zouridakis;given-names:G</infon><infon key="name_1">surname:Wadhawan;given-names:T</infon><infon key="name_2">surname:Situ;given-names:N</infon><infon key="name_3">surname:Hu;given-names:R</infon><infon key="name_4">surname:Yuan;given-names:X</infon><infon key="name_5">surname:Lancaster;given-names:K</infon><infon key="section_type">REF</infon><infon key="source">Mob. Health Technol</infon><infon key="type">ref</infon><infon key="year">2015</infon><offset>25633</offset><text>Melanoma and Other Skin Lesion Detection Using Smart Handheld Devices.</text></passage><passage><infon key="file">nihms-1023170-f0001.jpg</infon><infon key="id">F1</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>25704</offset><text>War on Melanoma™ Full Spectrum Operations Matrix. This shows different outreach and screening examples by risk class and different empowerment methods by provider type. Different provider types see different proportions of the various risk populations as represented with the heat map matrix. Provider and risk population classes are not the same size as represented by the shaded triangles.</text></passage></document></collection>
